Efficacy of Adagrasib in KRAS G12C-Mutant Solid Tumors
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On January 19, 2022, Dr. Tanios S. Bekaii-Saab and colleagues from the Mayo Clinic published findings in the Journal of Clinical Oncology regarding the efficacy and safety of the KRAS inhibitor Adagrasib in patients with advanced solid tumors harboring the KRAS G12C mutation, as evaluated in the KRYSTAL-1 Phase 1/2 clinical trial.
The KRYSTAL-1 trial was a multi-center study evaluating Adagrasib (600 mg twice daily) in patients with KRAS G12C-mutant advanced solid tumors (N = 42). The cohort focused on gastrointestinal and other non-lung/colorectal malignancies. The primary endpoints were objective response rate (ORR), safety, and pharmacokinetics.
Patient Demographics: The median age of participants was 63.5 years (range: 21–89). The cohort was 52% female and 71% Caucasian. Most patients (71%) had an ECOG performance status of 1. The median number of prior systemic therapies was two (range: 1–7). Among the 30 patients with gastrointestinal cancers, the primary sites were:
- Pancreatic Cancer: 12 patients
- Biliary Tract Cancer: 8 patients
- Appendiceal Cancer: 5 patients
- Gastroesophageal Junction Adenocarcinoma: 2 patients
- Small Bowel Cancer: 2 patients
- Esophageal Cancer: 1 patient
Clinical Outcomes: In the evaluable population (N = 27):
- Objective Response Rate (ORR): 41% (11/27 patients achieving partial response).
- Disease Control Rate (DCR): 100% (27/27 patients).
Specifically for Pancreatic Cancer (N = 12, evaluable N = 10):
- ORR: 50% (5/10 patients).
- DCR: 100% (10/10 patients).
- Median Progression-Free Survival (PFS): 6.6 months. At the time of reporting, 50% of pancreatic cancer patients remained on treatment.
For other gastrointestinal cancers (N = 17 evaluable):
- ORR: 35% (6/17 patients).
- DCR: 100% (17/17 patients). Eleven patients remained on treatment.
Safety and Tolerability: Treatment-related adverse events (TRAEs) occurred in 91% of patients (38/42). The most common side effects included:
- Nausea: 48%
- Diarrhea: 43%
- Vomiting: 43%
- Fatigue: 29% Grade 3–4 TRAEs were reported in 21% of patients, with zero Grade 5 events.
Conclusion: According to the KRYSTAL-1 results, Dr. Bekaii-Saab concluded that Adagrasib demonstrated promising anti-tumor activity and a manageable safety profile in patients with KRAS G12C-mutant pancreatic and other gastrointestinal cancers. Clinical evaluation of Adagrasib in this patient population is ongoing.
Source: Journal of Clinical Oncology (ASCO Publications)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4